back to blog roll
Jeff Mize Jeff Mize, RRT, CHT, UHMSADS | Updated on Nov 18, 2026

Overview

The Undersea and Hyperbaric Medical Society (UHMS) supports standardized terminology for the clinical delivery of hyperbaric oxygen. The Society’s preferred term is hyperbaric oxygen treatment, abbreviated HBO₂ or HBO₂ treatment.

The position statement was created June 1, 2026, with the next review scheduled for 2031. It was authored by Owen J. O’Neill, MD, MPH, FUHM; Mathew Kelly, MD; and Dag Shapshak, MD. It was reviewed and approved by the UHMS Publications Committee and submitted to the UHMS Board.

Preferred terminology

Historically, multiple terms have been used interchangeably, including:

  • Hyperbaric oxygen therapy
  • Hyperbaric oxygen treatment
  • Compression therapy
  • Recompression therapy
  • Hyperbaric chamber treatment

Abbreviations have similarly varied, including HBO, HBO₂, and HBOT.

The UHMS recommends the following nomenclature:

Preferred termPreferred abbreviation
Hyperbaric oxygen treatmentHBO₂ or HBO₂ treatment

The term hyperbaric oxygen therapy and the abbreviation HBOT should be phased out in professional communications in favor of the terminology adopted in current UHMS guidance and publications.

UHMS definition of clinical HBO₂ treatment

UHMS defines hyperbaric oxygen treatment as a medical procedure requiring physician prescription and oversight. The patient must:

  • Have the entire body placed within a hard-sided hyperbaric chamber
  • Receive treatment in a chamber meeting applicable ASME PVHO-1 and NFPA 99 standards
  • Be exposed to pressure of at least 2.0 ATA (202.65 kPa)
  • Breathe physician-prescribed medical-grade oxygen
  • Receive oxygen with purity greater than 99.0%
  • Undergo a treatment typically lasting 90–120 minutes

These parameters distinguish UHMS-defined clinical HBO₂ treatment from other forms of pressure exposure.

Rationale for terminology standardization

The UHMS identifies several reasons for adopting standardized terminology:

  • To clarify the definition of clinical hyperbaric oxygen treatment
  • To distinguish physician-supervised HBO₂ treatment from non-standardized interventions
  • To reduce confusion among patients, referring clinicians, payers, regulators, and the public
  • To reinforce that hyperbaric medicine is a medically regulated discipline
  • To promote consistency in scientific, educational, operational, and professional communications
  • To align terminology with the current UHMS Hyperbaric Medicine Indications Manual and related publications

The term treatment more accurately reflects the structured, protocol-based, physician-supervised nature of the intervention.

Distinguishing clinical HBO₂ treatment from “mild hyperbaric” services

The UHMS notes that some commercial services use terms such as mild hyperbaric or wellness-based pressure exposure for interventions involving variable oxygen concentrations, pressures, or treatment parameters.

Some low-pressure or soft-sided chambers may:

  • Operate outside UHMS-defined treatment parameters
  • Not meet applicable ASME PVHO-1 or NFPA 99 standards
  • Lack the characteristics required for clinical HBO₂ treatment

Clinicians should therefore use terminology that clearly differentiates UHMS-defined HBO₂ treatment from non-standardized commercial pressure-based services.

Implications for HBO₂ clinicians

HBO₂ clinicians and programs should use hyperbaric oxygen treatment and HBO₂ treatment in:

  • Medical records and operational documents
  • Treatment protocols and policies
  • Patient and provider education
  • Scientific manuscripts and presentations
  • Institutional communications
  • Professional correspondence
  • Hyperbaric facility materials

The terminology should be applied consistently across clinical and administrative communications.

Coding and reimbursement

The UHMS recognizes that existing reimbursement terminology, coding language, and legacy literature may continue to use hyperbaric oxygen therapy or HBOT.

This position statement establishes preferred professional nomenclature for future communications. It does not modify existing coding or reimbursement frameworks.

Key takeaways

  1. Use hyperbaric oxygen treatment as the preferred clinical term.
  2. Use HBO₂ or HBO₂ treatment as the preferred abbreviation.
  3. Phase out hyperbaric oxygen therapy and HBOT in new professional, educational, scientific, and operational materials.
  4. Reserve clinical HBO₂ terminology for treatment meeting UHMS-defined clinical, equipment, oxygen, pressure, and physician-oversight standards.
  5. Clearly distinguish UHMS-defined HBO₂ treatment from commercial “mild hyperbaric” or wellness-based pressure exposure services.
  6. Continue using existing coding and reimbursement terminology where required.

About the Authors

Jeff Mize, RRT, CHT, UHMSADS
With over four decades of healthcare experience, Jeff currently holds the position of Principal Partner at Midwest Hyperbaric LLC and the Co-founder and Chief Clinical Officer of Wound Reference. Jeff has excelled in critical care throughout his career, devoting almost a decade as a Flight Respiratory Therapist/Paramedic for the Spirit of Kansas City Life Flight. In 1993, Jeff transitioned into the field of Hyperbaric Medicine and Wound Care, where he committed 21 years of his career to serving as the Program Director for a 24/7 Level 1 UHMS Accredited facility with Distinction. In this role, he continued to provide patient care while overseeing all administrative, clinical, and daily operations within the Wound Care and Hyperbaric Facility. Jeff is a Registered Respiratory Therapist and a Certified Hyperbaric Technologist (CHT). He has also undergone training as a UHMS Safety Director and a UHMS Facility Accreditation Surveyor. Jeff currently serves as a member of the UHMS Accreditation Council, the UHMS Accreditation Forum Expert Panel, and the UHMS Safety Committee. Additionally, he is an esteemed member of the NFPA 99 Hyperbaric and Hypobaric Facilities Technical Standards Committee. Jeff's dedication to the field has earned him numerous prestigious awards. In 2010, he received the Gurnee Award, which honored his outstanding contributions to undersea and hyperbaric medicine. Three years later, in 2013, he was awarded the Paul C. Baker Award for his commitment to Hyperbaric Oxygen Safety Excellence. Most recently, in 2020, Jeff was honored with "The Associates Distinguished Service Award (UHMSADS)," a recognition reserved for exceptional Associate members of the Society who have demonstrated exceptional professionalism and contributions deserving of the highest accolades.
Explore our Wound Care and Hyperbaric Solutions
t
-->